% | $
Quotes you view appear here for quick access.


  • jm4452000 jm4452000 Oct 30, 2011 10:06 AM Flag

    Casey eye expo 10/29/2011

    There was an expo on vision 10/29/2011 I picked up the news and site on I cell. Below is a list of drugd for AMD and the results they achieve. Check out the expo for additional information.

    The anti-angiogenic drugs described below block a protein called vascular endothelial growth factor, or VEGF (pronounced vej-ef). Growth factors like VEGF stimulate abnormal blood vessels to proliferate. These agents block VEGF so that eye cells no longer receive the message to make damaging new blood vessels.

    Lucentis(ranibizumab): This drug shows excellent results. More than 90 percent of patients treated with Lucentis in clinical trials maintained their vision at or near their initial visual acuity after one year of treatment. The vision of nearly one-third of study patients improved by at least three lines (or 15 letters) on the eye chart. Some people do not respond well to Lucentis, although it is not clear why. A clinical trial is being conducted to learn if underlying genetic factors play a role. Researchers are studying the patient's response to treatment and analyzing their DNA and lifestyle habits. These findings may lead to the development of medications personalized to the patient's own gene structure.

    Avastin (bevacizumab): Also widely used to treat wet AMD, this drug is closely related to, but much less expensive than Lucentis. Casey researchers are conducting a multicenter clinical trial comparing Avastin and Lucentis for the treatment of AMD. Results from the first year of the two-year study show that the drugs are equally safe and effective in preserving vision. Researchers will continue to follow participants through the second year of treatment to learn more about the long-term effects of these medications on vision, safety and dosing.

    Macugen (pegaptanib): This was the first anti-VEGF drug for AMD to be approved by the FDA. Macugen is less effective than Lucentis and Avastin and consequently is no longer in common use for wet AMD.

    Photodynamic Therapy (PDT): Before anti-angiogenic medications like Lucentis and Avastin were introduced, photodynamic therapy - or PDT - had been the primary treatment for wet AMD. The procedure involves the administration of a light sensitive drug in conjunction with a low intensity laser, which seals off the abnormal, leaking blood vessels. PDT is less commonly used, but continues to play a limited role in treating wet AMD. It is being investigated for use in combination with other drugs, particularly in situations where response is poor to other treatments.

    Laser Therapy for Wet AMD: For more than 20 years, conventional laser therapy was the only proven effective therapy for wet AMD. However, its effects were limited and the number of cases eligible for treatment was small. Newer methods of treatment using medications are now indicated for most patients with wet AMD. There remains, however, certain selected cases for which laser may be appropriate.

    SortNewest  |  Oldest  |  Most Replied Expand all replies